A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies

Bispecific T cell engagers (bsTCEs) hold great promise for cancer treatment but face challenges due to the induction of cytokine release syndrome (CRS), on-target off-tumor toxicity, and the engagement of immunosuppressive regulatory T cells that limit efficacy. The development of Vγ9Vδ2-T cell enga...

Descripción completa

Detalles Bibliográficos
Autores principales: Lameris, Roeland, Ruben, Jurjen M., Iglesias-Guimarais, Victoria, de Jong, Milon, Veth, Myrthe, van de Bovenkamp, Fleur S., de Weerdt, Iris, Kater, Arnon P., Zweegman, Sonja, Horbach, Sjeng, Riedl, Thilo, Winograd, Benjamin, Roovers, Rob C., Adang, Anton E.P., de Gruijl, Tanja D., Parren, Paul W.H.I., van der Vliet, Hans J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040383/
https://www.ncbi.nlm.nih.gov/pubmed/36868236
http://dx.doi.org/10.1016/j.xcrm.2023.100961

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040383/
https://www.ncbi.nlm.nih.gov/pubmed/36868236
http://dx.doi.org/10.1016/j.xcrm.2023.100961

Ejemplares similares